Kit for screening spinal muscular atrophy virulence gene carrier and application of kit

A spinal muscular atrophy and pathogenic gene technology, applied in DNA/RNA fragmentation, DNA preparation, recombinant DNA technology, etc., can solve the problems of poor reliability, complicated operation, low accuracy, etc., and achieve good reliability and repeatability. Good, accurate results
CN105039318AInactive Publication Date: 2015-11-11SUZHOU VOCATIONAL UNIV +1

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
SUZHOU VOCATIONAL UNIV
Publication Date
2015-11-11
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The invention discloses a kit for screening a spinal muscular atrophy (SMA) virulence gene carrier and application of the kit, and belongs to the field of gene detection. The copy number of exon7 of a main virulence gene SMN1 of spinal muscular atrophy is quantitatively detected by a fluorescent quantitation PCR method based on a Taqman probe, so that distinguishing between the spinal muscular atrophy virulence gene carrier and a non carrier is realized. The kit can be quickly and conveniently applied to screening the spinal muscular atrophy virulence gene carriers from a large scale of people, is particularly suitable for screening on antenatal, premarital and pre-pregnant people and gene diagnosis on patients and is high in repetitiveness and accurate in result.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention particularly relates to a kit and a screening method which can be used for screening the pathogenic gene carriers of spinal muscular atrophy, belonging to the field of gene detection. Background technique

[0002] Spinal muscular atrophy (SMA) is a neuromuscular disease that is inherited as an autosomal recessive disorder. It affects 1 in 6,000 births. The clinical manifestations are progressive, symmetrical muscle atrophy and muscle weakness. So far, there is no effective treatment for SMA, and the prognosis is mainly related to the type of disease. The general survival time of type I patients is less than 2 years old, the survival time of type II patients is less than 5 years old, and the type III patients can survive to adulthood. Slow, eventually died of respiratory muscle paralysis, or systemic failure.

[0003] Two genes related to SMA have been found so far, namely neuronalapoptosisinhibitoryprotein (NAIP) and motor neuron survi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More